Nektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails

seekingalpha2022-03-14

Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • KCKHOO
    2022-03-15
    KCKHOO
    Like
  • SCLIEW
    2022-03-15
    SCLIEW
    666
  • BenjiFuji
    2022-03-15
    BenjiFuji
    Better to fail at phase 3 than realise it's a mistake at phase 4.
  • WaiSiong81
    2022-03-15
    WaiSiong81
    👍
  • stylus
    2022-03-15
    stylus
    Oops 😬 
  • Chonky
    2022-03-15
    Chonky
    Like please 
Leave a comment